Compare EVAX & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVAX | AYTU |
|---|---|---|
| Founded | 2008 | N/A |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.5M | 27.4M |
| IPO Year | 2020 | 2015 |
| Metric | EVAX | AYTU |
|---|---|---|
| Price | $2.90 | $1.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $12.25 | $9.67 |
| AVG Volume (30 Days) | ★ 129.0K | 26.0K |
| Earning Date | 11-19-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,632,080.00 |
| Revenue This Year | N/A | $17.96 |
| Revenue Next Year | N/A | $27.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $2.67 | $1.75 |
| 52 Week High | $6.92 | $3.07 |
| Indicator | EVAX | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 45.94 | 37.93 |
| Support Level | $2.90 | N/A |
| Resistance Level | $3.56 | $2.34 |
| Average True Range (ATR) | 0.31 | 0.10 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 18.80 | 25.93 |
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.